In the last few weeks, the fast spread of the SARS-CoV-2 is accompanied by the fast spread of fake news that lead to useless alarmism and mainly false expectations.
To better face this emergency, it is not only crucial to follow the rules released by the government, but it is important as well to be correctly informed and be aware of the shared information.
Follow our tips to recognise the fake news and to have a proactive role in this circumnstance.
To this end, Fondazione Gianni Benzi reports up to date and verified news. Particularly today, we focused on the actions undertaken by the dall’Agenzia Italiana del Farmaco (AIFA), in order to identify possible therapies for COVID-19.
To promote the early access to treatments and to facilitate the conduction of clinical studies on novel therapies, AIFA is actively involved in different fields:
- Adoption of off label medicines used for an indication different from the authorized one, such as two antimalarials (Chloroquine and Hydroxychloroquine) with a potential antiviral activity and drugs used for the treatment of the HIV infection (Lopinavir/Ritonavir and subordinately with Darunavir in combination with Covicistat o Ritonavir). Another therapeutic option that has recently been successfully used on patients with COVID-19, is Tocilizumab a monoclonal antibody currently adopted for the rheumatoid arthritis. AIFA authorised a study that will test the efficacy and safety of this medicine for COVID-19. The study is promoted by Istituto Nazionale per lo Studio e la Cura dei Tumori in Naples in collaboration with Università degli Studi di Modena e Reggio Emilia, IRCCS in Reggio Emilia and with the AIFA Scientific Board.
- Clinical study and access to novel therapies, in particular Remdesvir, a not authorised antiviral, that will be tested in two clinical trials, promoted by AIFA and that has been authorised for compassionate use in patients in serious conditions.
Stay tuned for further updates!